top of page

MOXI Trial



MOXI is a research study of heterosexual couples who are experiencing infertility.

The purpose of MOXI is to see if a daily antioxidant combination will help with male fertility. 

Male partners during the MOXI trial will receive daily vitamins or placebo which they will take for up to six months. Male partners will also provide blood and semen samples at certain times during the study.

MOXI is important because it could lead to a non-hormonal treatment for male infertility.



Couples are eligible to participate if they:

  • Have been trying to get pregnant for a year or more

  • Are heterosexual

  • Are living together and are able to have regular intercourse


Couples are not eligible to participate if:

  • The female partner has a history of endometriosis

  • The female partner has a BMI of over 35 kg/m2

  • The female partner has a history of polycystic ovarian syndrome (PCOS)

  • Either partner has had any sterilization procedures (vasectomy, tubal ligation)



Screening Visit:
Male and Female partners will come into the clinic to meet with the study team and to see if you are eligible to participate.

Study Visits:
If you and your partner are eligible, you will come into the office for 4 study visits (for males) or 2 study visits (for females). Male partners will be asked to provide semen samples throughout the study. Both partners will provide blood and urine samples.

Male partners will be given an antioxidant combination or placebo to take every day for up to 6 six months. Neither you nor the study staff will know which treatment you will receive. 

Following three months of antioxidant therapy, female partners will begin infertility treatments for up to 3 cycles.



  • Participants receive up to 6 months of antioxidant treatment

  • Participants may receive up to 3 cycles of infertility treatment (clomid/IUI)

  • Ovulation predictor kits and pregnancy tests

  • Satisfaction of knowing you are contributing to our knowledge about infertility


Closed to recruitment 

Principal Investigator:
Christos Coutifaris, MD, PhD

bottom of page